Airfinity RSV Intelligence (1)

Airfinity's RSV intelligence solution includes independent analysis and forecasts across all candidates in clinical development and post-approval.

As the RSV market continues to develop rapidly, Airfinity is committed to continued expansion of its data and intelligence coverage. In response to recent approvals, we have added data around eligible populations in each country, as well as pricing and reported revenues for the approved candidates.

Eligible Population: Understand where RSV candidates have gained approval and which populations are eligible to receive these newly approved vaccines and prophylactics. This expanded functionality allows you to:

→ Identify which markets RSV candidates have gained approval in

→ See how the eligible populations in each market differs

→ Compare the timelines of approvals in different markets

→ Understand nuances of approvals and roll-out with extra information provided e.g. shared decision making

Pricing Data: Access all publicly available pricing data across vaccines and prophylactics including public and private pricing across markets, income bands and regions. This allows you to compare pricing data across market, region, income band, country and candidate

Revenue Data: Q3 revenue data has recently been released for the first time from Sanofi for Nirsevimab, and from GSK and Pfizer for their RSV vaccines. These new reported revenue figures are now available on the platform, alongside previous reported revenues for Palivizumab. These will continue to be tracked and updated as new revenue data is released.

Get in touch to book your free demo!

Airfinity is also monitoring and collecting supply data, this will be represented on the platform in the coming weeks. Get your sneak preview by booking your demo now.

Science360 Laptop Mock Image

Get in touch to book your free demo!

Airfinity is also monitoring and collecting supply data, this will be represented on the platform in the coming weeks. Get your sneak preview by booking your demo now.

Analysis & Insights

The West should be on a war footing for the next pandemic
The West should be on a war footing for the next pandemic

The COVID-19 pandemic is not a once in a lifetime risk, the next deadly virus could emerge sooner than we think. Western allies need to be prepared and should be on a constant war footing for the next outbreak.

Read More →


More from Airfinity

Democracies are better at managing pandemics than autocracies, according to a new study by Airfinity

From resistance to resilience: what could the future antibiotic pipeline look like?

Airfinity further expands into APAC with launch of Japan office

Stockpiles worth $1.1 billion of COVID-19 antiviral pill Paxlovid have expired in UK and Europe

Airfinity Named The Financial Times' Healthcare Tech Champion 2023

Airfinity upgrades global biorisk platform

Airfinity named among Bloomberg’s UK Startups to Watch 2023

View All →

In the News

New Covid FLiRT Variants Have the FDA Weighing a Vaccine Update

Bloomberg | May 23, 2024

The West should be on a war footing for the next pandemic

The Telegraph | May 22, 2024

The HIV response beyond 2030: preparing for decades of sustained HIV epidemic control in eastern and southern Africa

The Lancet | May 20, 2024

Democracies are better at managing pandemics than autocracies, according to a new study by Airfinity

AP News | May 15, 2024

View All →